Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world post-marketing safety re-evaluation study of traditional Chinese medicine injections
ChiCTR1900024340Phase 4Recruiting
- Sponsor
- Shi Qingping
- Start
- Jun 2019
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bazhengsan in cardiac morbidity and cerebrovascular disease, sponsored by Shi Qingping. Primary endpoint: Adverse reactions. Started Jun 2019; status: recruiting.
02
Drugs
bazhengsan
03
Conditions
cardiac morbiditycerebrovascular disease
Beyond the preview
Go deeper on ChiCTR1900024340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024340.